Atossa Therapeutics (ATOS) AI Stock Analysis

• Market Cap: $103.98M
• Dividend Yield: N/A
• Average Volume (3M): 1.66M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: N/A
• EPS Growth: 15.09%
• Country: US
• Employees: 15
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 129,170,000
• 10 Day Avg. Volume: 2,056,367
• 30 Day Avg. Volume: 1,656,617
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.21
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -5.42K
• Enterprise Value/Ebitda: -1.05
• 1Y Price Target: $5.63
• Price Target Upside: 631.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 36 Underperform
• Price Target: ―

Atossa Therapeutics' stock score is weighed down by significant financial challenges, including ongoing operational losses and negative cash flow, despite a debt-free balance sheet. Technical indicators suggest short-term overbought conditions, while the valuation remains unattractive due to a lack of profitability and dividends. Although the earnings call provided some positive guidance on cost reductions and clinical progress, these are overshadowed by the company's financial instability.

Positive Factors

Clinical Trials

Positive topline data from the KARISMA-Endoxifen Phase 2 study demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density and was well tolerated.

FDA Approval

Positive FDA feedback for Endoxifen provides a path to the IND for a registration enabling study in ER+/HER2- metastatic breast cancer.

Financial Performance

Atossa remains well-capitalized with ~$65M in cash, providing sufficient runway well into 2027.

Negative Factors

Development Risks

While there are high risks due to the long development road and potential for clinical trial failures, the market potential of approximately a billion dollars presents high rewards for these risks.

Market Competition

The oral SERD space in second-line and beyond patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.

Atossa Therapeutics Business Overview & Revenue Model

Company Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

How the Company Makes Money

Atossa Therapeutics primarily generates revenue through strategic partnerships and collaborations with other pharmaceutical companies, licensing agreements, and potential milestone payments related to the development and commercialization of its drug candidates. As a clinical-stage company, revenue is also contingent upon successful clinical trial results and subsequent regulatory approvals. Additionally, Atossa may engage in fundraising activities to support its ongoing research and development efforts.

Atossa Therapeutics Financial Statement Overview

Summary

Atossa Therapeutics faces significant financial challenges, reflected in its inability to generate revenue and ongoing operational losses. While the company benefits from a debt-free balance sheet and strong equity, its cash flow situation is concerning, with negative cash flow metrics indicating reliance on external financing. The overall financial health is weak, necessitating strategic changes to improve revenue generation and operational efficiency.

Income Statement

Atossa Therapeutics has consistently reported zero revenue over the years, with increasing net losses, reflecting challenges in achieving profitability. The TTM (Trailing-Twelve-Months) data shows a worsening net loss, indicating further financial strain. The absence of revenue growth and negative profit margins highlight significant operational challenges.

Balance Sheet

The company maintains a strong equity position with no debt, which is a positive financial indicator. However, the consistent net losses and decreasing equity over time raise concerns about the sustainability of its financial position. The equity ratio remains high, suggesting financial stability despite operational losses.

Cash Flow

Atossa Therapeutics exhibits negative operating and free cash flow, indicating cash burn due to ongoing operational expenses without revenue generation. The company relies on financing activities to support operations, which may not be sustainable in the long term without revenue growth. The cash flow ratios indicate inefficiency in converting cash flow into profits, raising concerns over liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-17.00K	-23.00K	-8.00K	-23.00K	-46.60K
EBITDA	-25.49M	-31.35M	-27.68M	-20.50M	-14.56M
Net Income	-25.50M	-30.09M	-26.23M	-20.61M	-21.10M
Balance Sheet
Total Assets	76.44M	96.25M	123.53M	141.26M	42.84M
Cash, Cash Equivalents and Short-Term Investments	71.08M	88.46M	110.89M	136.38M	39.55M
Total Debt	0.00	0.00	0.00	0.00	18.05K
Total Liabilities	4.97M	5.24M	5.57M	3.13M	15.67M
Stockholders Equity	71.48M	91.02M	117.96M	138.14M	27.17M
Cash Flow
Free Cash Flow	-21.05M	-20.95K	-20.79M	-16.48M	-11.58M
Operating Cash Flow	-21.03M	-20.94K	-20.76M	-16.47M	-11.57M
Investing Cash Flow	-19.00K	-14.00	-4.73M	-9.00K	-9.37K
Financing Cash Flow	3.67M	-1.48K	0.00	113.30M	38.55M

Atossa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOS, the sentiment is Negative. The current price of 0.77 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 0.85, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.09 is Neutral, neither overbought nor oversold. The STOCH value of 1.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATOS.

Atossa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$2.60B	3.64	-58.14%	2.69%	36.37%	13.78%
ANIX	49 Neutral	$101.46M	―	-61.14%	―	-100.00%	-24.28%
SNTI	47 Neutral	$44.86M	―	-169.54%	―	-100.00%	24.59%
ZURA	43 Neutral	$97.14M	―	-62.34%	―	―	86.65%
PLRX	37 Underperform	$103.74M	―	-63.22%	―	-100.00%	-26.44%
ATOS	36 Underperform	$103.98M	―	-34.87%	―	―	15.09%
HLVX	35 Underperform	$102.79M	―	-40.31%	―	―	1.27%